The discovery and preclinical validation of a novel gene signature predictive for response to HDM2-targeting drug NVP-CGM097 could significantly improve the clinical response rate to all p53-HDM2 inhibitors.

Real-time ³³P imaging combined with specific complementation of inorganic phosphate transport in the root cap reveals this tissue’s contribution to phosphate uptake.

PHF13 interacts with transcriptional complexes containing RNA polymerase II to recruit/stabilize them at H3K4me2/3 containing active or bivalent promoters.

By binding to Fc gamma receptor IIb, amyloid beta induces a series of phosphorylation events that mediate the damaging effects of hyperphosphorylated tau proteins in Alzheimer's disease.

Conserved contacts on cognate ligands trigger an induced fit pathway that confers selective promiscuity to PD-1, a flexible regulatory protein and promising anticancer target.

The unwrapping two turns of DNA on Chd1-bound nucleosomes cause the histone H3 tail and ubiquitin to be re-positioned.

Aβ inhibitors effectively block its aggregation, while also reducing seeding of tau aggregation from Aβ, tau, and AD derived fibrils, suggesting the two share a structurally related disease relevant interface.

The two H2A.Z isoforms have specific interactors which mediate their differential effects on gene expression.

Depletion of PHF19 in prostate cancer cells leads to an increase in MTF2 and PRC2 chromatin occupancy causing deregulation of key genes critical for proliferation and metastasis.

Complex structures of Tudor domains of PHF1/19 with H3tK27me3 provide structural basis for preferential recognition of H3tK27me3 over canonical H3K27me3, implicating that H3tK27me3 might be a physiological ligand of PHF1/19.